Detection of serum peptides enable the diagnosis of relapsing polychondritis

2021 Fiscal Year Final Research Report

• Project/Area Number: 19K05721
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 37020:Chemistry and chemical methodology of biomolecules-related
• Research Institution: St. Marianna University School of Medicine
• Principal Investigator: Sato Toshiyuki 聖マリアンナ医科大学, 医学部, 助教 (10350430)
• Project Period (FY): 2019-04-01 – 2022-03-31
• Keywords: 再発性多発軟骨炎 / 血清 / 血清ペプチド / 診断マーカー / バイオマーカー / ペプチドミクス

Outline of Final Research Achievements

In the RP group, 27, 9, and 9 peptides showed ion intensity at least 1.2-fold higher or lower in comparison to the HC, RA, and HC+RA (non-RP) groups in the training set, the cohort for the construction of RP-discriminant model, respectively (p<0.05). Selecting 11, 9, and 14 peptides by multivariate analysis, we completely discriminated the RP group from those groups, respectively in the training set. We tried to identify the peptides as described above. As a result, 19 peptides were identified and the most identified peptides were derived from proteins associated with coagulation. Selecting any 4 out of 10 identified peptides used in the discrimination of RP and non-RP groups, we generated 4 RP/nonRP-discriminant models with both sensitivity and specificity of 70.0% or more in testing set, the cohort for the validation of the discriminant model, and testing set with 7 granulomatosis with polyangiitis.

Free Research Field

ペプチドミクス

Academic Significance and Societal Importance of the Research Achievements

学術的意義は、「血中ペプチドをバイオマーカーとして捉えた点」である。血中蛋白質は、99%を主要な蛋白質、残り1%を多様な蛋白質・小蛋白質（ペプチド）が占める。代表者のグループは顕微鏡的多発血管炎活動期にのみ検出される血清ペプチドの検出、レビー小体型認知症（DLB）で感度・特異度共に約90％を示すマーカー候補血清ペプチド及びアルツハイマー型認知症（AD）とDLBとを90％以上の確率で判別する血清ペプチドの検出など、ペプチドミクスで診断マーカー開発に応用している。社会的意義は、バイオマーカー研究を治療応用に繋げる点、である。いわば本研究は「バイオマーカー学」を樹立するものである。